Vericel Past Earnings Performance
Past criteria checks 3/6
Vericel's earnings have been declining at an average annual rate of -0.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 13.7% per year. Vericel's return on equity is 1.4%, and it has net margins of 1.6%.
Key information
-0.5%
Earnings growth rate
0.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 13.7% |
| Return on equity | 1.4% |
| Net Margin | 1.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Nov 09
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
Jul 12Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Apr 26Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Mar 02Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Feb 02Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
May 05Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy
Oct 10Vericel Q2 2022 Earnings Preview
Aug 02Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)
Apr 19Vericel - A Disruptive Business With Years Of Growth Remaining
Apr 12Vericel: In The Middle Of Difficulty Is An Opportunity
Dec 31Revenue & Expenses Breakdown
How Vericel makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 227 | 4 | 139 | 25 |
| 30 Jun 24 | 215 | 1 | 131 | 24 |
| 31 Mar 24 | 208 | 0 | 126 | 22 |
| 31 Dec 23 | 198 | -3 | 121 | 21 |
| 30 Sep 23 | 185 | -10 | 117 | 21 |
| 30 Jun 23 | 178 | -13 | 114 | 21 |
| 31 Mar 23 | 169 | -17 | 111 | 20 |
| 31 Dec 22 | 164 | -17 | 107 | 20 |
| 30 Sep 22 | 159 | -18 | 106 | 19 |
| 30 Jun 22 | 155 | -16 | 102 | 18 |
| 31 Mar 22 | 158 | -11 | 101 | 18 |
| 31 Dec 21 | 156 | -7 | 98 | 16 |
| 30 Sep 21 | 154 | 0 | 90 | 15 |
| 30 Jun 21 | 152 | 9 | 83 | 14 |
| 31 Mar 21 | 132 | 4 | 73 | 13 |
| 31 Dec 20 | 124 | 3 | 69 | 13 |
| 30 Sep 20 | 118 | 0 | 67 | 13 |
| 30 Jun 20 | 117 | 0 | 66 | 13 |
| 31 Mar 20 | 123 | -12 | 66 | 31 |
| 31 Dec 19 | 118 | -10 | 61 | 30 |
| 30 Sep 19 | 110 | -14 | 58 | 30 |
| 30 Jun 19 | 102 | -18 | 56 | 30 |
| 31 Mar 19 | 95 | -3 | 52 | 13 |
| 31 Dec 18 | 91 | -8 | 49 | 14 |
| 30 Sep 18 | 83 | -13 | 45 | 14 |
| 30 Jun 18 | 75 | -17 | 41 | 14 |
| 31 Mar 18 | 73 | -15 | 38 | 13 |
| 31 Dec 17 | 64 | -17 | 36 | 13 |
| 30 Sep 17 | 57 | -26 | 33 | 14 |
| 30 Jun 17 | 54 | -29 | 32 | 14 |
| 31 Mar 17 | 50 | -31 | 30 | 15 |
| 31 Dec 16 | 54 | -27 | 27 | 15 |
| 30 Sep 16 | 53 | -26 | 25 | 18 |
| 30 Jun 16 | 54 | -23 | 24 | 19 |
| 31 Mar 16 | 54 | -22 | 23 | 18 |
| 31 Dec 15 | 51 | -23 | 22 | 19 |
| 30 Sep 15 | 50 | -20 | 21 | 17 |
| 30 Jun 15 | 49 | -23 | 20 | 21 |
| 31 Mar 15 | 40 | -25 | 17 | 22 |
| 31 Dec 14 | 29 | -26 | 13 | 21 |
| 30 Sep 14 | 14 | -26 | 10 | 18 |
| 30 Jun 14 | 4 | -21 | 7 | 13 |
| 31 Mar 14 | 0 | -22 | 5 | 11 |
| 31 Dec 13 | 0 | -21 | 6 | 15 |
Quality Earnings: VCEL has high quality earnings.
Growing Profit Margin: VCEL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VCEL has become profitable over the past 5 years, growing earnings by -0.5% per year.
Accelerating Growth: VCEL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VCEL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: VCEL's Return on Equity (1.4%) is considered low.